| 1718GCCC-S14 | Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia; Age 60 years | Open |
| 1718GCCC-S5 | A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia >/= Age 60 years | Open |
| 1718GCCC-S6 | A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age >/= 18 years | Open |
| 19113GCCC | 19113GCCC: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML) | Open |
| 1972GCCC | GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Open |
| 2087GCCC | 2087GCCC: Pegcrisantaspase in combination with venetoclax for treatment of relapsed or refractory acute myeloid leukemia (R/R AML) | Open |
| 2099GCCC | 2099GCCC: A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients with Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotypic Acute Leukemia (MPAL) | Not Open |